Shopping Cart 0
Cart Subtotal
USD 0

Illumina Inc (ILMN) - Medical Equipment - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company's portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina caters its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations. The company sells its products through direct sales and distributors in the Americas, Asia-Pacific, Europe, the Middle East and Africa. Illumina is headquartered in San Diego, California, the US.

Illumina Inc (ILMN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 8

Illumina Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Illumina Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 11

Illumina Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Illumina Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 13

Illumina Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 14

Illumina Inc, Medical Equipment, Deal Details 19

Venture Financing 19

Grail Raises USD300 Million in Series C Financing 19

Cernostics Raises USD2.5 Million in Series A1 Financing 20

SerImmune Raises USD8 Million in Venture Financing 21

Grail Raises USD914 Million in First Tranche of Series B Financing 22

Human Longevity Raises USD220 Million in Series B Financing Round 24

Grail Bio Raises USD100 Million in Series A Financing 26

Vitagene Raises Funds in Financing Round 27

23andMe Raises USD115 Million in Series E Financing 28

Baebies Raises USD13 Million in Financing Round 30

Verinata Health (Artemis Health) Secures USD1.2 Million in Seed Funding 31

Oxford Nanopore Raises USD 64 Million In Venture Financing 32

GenoLogics Life Sciences Raises USD0.9 Million in Venture Financing 34

GenoLogics Life Sciences Raises Additional USD0.5 Million in Venture Financing 35

GenoLogics Life Sciences Raises USD1.3 Million in Venture Financing 36

Private Equity 37

Mubadala GE Capital and SoftBank Vision Fund May Acquire GRAIL 37

Partnerships 38

Vitrolife Enters into Licensing Agreement with Illumina 38

CareDx Enters into Licensing and Commercialization Agreement with Illumina 39

Skyline Medical Enters into Licensing Agreement with Illumina 40

Illumina Enters Into Licensing Agreement With Quest Diagnostics 41

Peter MacCallum Cancer Centre Enters Into Licensing Agreement With GenoLogics Life Sciences Software For Clarity LIMS 42

Genecast Biotechnology Enters into Partnership Agreement with Illumina 43

Yissum Enters into Agreement with GRAIL 44

Bristol-Myers Squibb and Illumina Enter into Partnership Agreement 45

Illumina and Loxo Oncology Enter into Partnership 46

Illumina and KingMed Diagnostics Enter into Agreement 47

Illumina Enters into Agreement with Pillar Biosciences 48

Edico Genome Enters Into Partnership With Fabric Genomics 49

Hamilton Robotics Partners with Illumina 50

Lucigen Enters into Distribution Agreement with Illumina 51

Kailos Genetics Enters into Co-Marketing Agreement with Illumina 52

Analytik Jena Enters into Co-Development Agreement with Illumina 53

Bristol-Myers Squibb Plans to Enter into Research Agreement with GRAIL 54

Invivoscribe Tech Enters into Agreement with Illumina 55

IBM Watson Health Enters into Agreement with Illumina 56

Koninklijke Philips Enters into Agreement with Illumina 57

Illumina Enters into Agreement with Mayo Clinic 58

Q2 Solutions Enters into Co-Development Agreement with Illumina 59

Sophia Genetics Enters into Co-Marketing Agreement with Illumina 60

Illumina Enters into Agreement with FlowJo 61

Personal Genome Diagnostics Enters into Co-Development Agreement with Illumina 62

MolecularMD Enters into Agreement with Illumina 63

ArcherDX Enters into Co-Development Agreement with Illumina 64

Genomics England Partners with Illumina 65

Bio-Rad Laboratories Enters into Partnership with Illumina 66

Novogene Enters into Co-Development Agreement with Illumina 67

Almac Diagnostics Enters into Agreement with Illumina 68

Centers for Disease Control and Prevention Enters into Research Agreement with Edico Genome 69

Asuragen to Enter into Agreement with Illumina 70

Edico Genome Enters into Agreement with HudsonAlpha Institute for Biotechnology 71

Illumina Enters into Co-Development Agreement with Annoroad Gene Technology 72

Merck Serono Enters into Co- Development Agreement with Illumina 73

Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT 74

BioMerieux Enters into Co-Development Agreement with Illumina 75

Sequenta Enters into Agreement with Illumina to Commercialize In Vitro Diagnostic Kit 76

Reprogenetics Enters into R&D Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems 77

HTG Molecular Diagnostics Amends its Agreement with Illumina to Develop IVD Kits for Sequencing Tests 78

Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 79

Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 80

Pathogenica Enters Into Co-Marketing Agreement With Illumina 81

Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 82

Illumina Enters Into Co-Marketing Agreement With Hamilton Robotics 83

SynapDx Enters Into Co-Development Agreement With Illumina For Autism Diagnostic Tools 84

Sonic Healthcare Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 85

Newbridge Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 86

NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers 87

PerkinElmer Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 88

NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 89

Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 90

GenMark Diagnostics Enters Into Co-Development Agreement With Advanced Liquid Logic For Integrated Diagnostic Platform 91

Merger 92

Grail Merges with Cirina 92

Equity Offering 93

Grail May Raise USD1 Billion in IPO 93

Debt Offering 94

Illumina Prices Private Placement of Notes Due 2023 for USD650 Million 94

Illumina Raises USD550 Million in Private Placement of Notes Due 2019 96

Illumina Raises USD450 Million in Private Placement of 0.5% Notes Due 2021 97

Asset Transactions 98

Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 98

Pathway Genomics Acquires MiSeqDx From Illumina 99

Novogene Acquires HiSeq X Ten Sequencing System From Illumina 100

Acquisition 101

Illumina Acquires Edico Genome 101

Thermo Fisher Scientific May Acquire Illumina for USD30 Billion 102

Illumina Acquires Conexio Genomics 103

Illumina Acquires Myraqa, In-Vitro Diagnostics Company 104

Illumina Acquires NextBio, Clinical and Genomic Informatics Company 105

Illumina Completes Sale Of 13.5% Stake In Oxford Nanopore For USD 91 Million 106

Illumina Acquires Advanced Liquid Logic 107

Illumina Completes Acquisition Of Verinata Health 108

Illumina Acquires Moleculo, Long-Read Sequencing Technology Developer 110

Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization Screening Solutions 111

Illumina Inc-Key Competitors 112

Illumina Inc-Key Employees 113

Illumina Inc-Locations And Subsidiaries 114

Head Office 114

Other Locations & Subsidiaries 114

Joint Venture 116

Recent Developments 117

Financial Announcements 117

Jul 30, 2018: Illumina Reports Financial Results for Second Quarter of Fiscal Year 2018 117

Apr 24, 2018: Illumina Reports Financial Results for First Quarter of Fiscal Year 2018 119

Jan 30, 2018: Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2017 120

Oct 24, 2017: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2017 122

Aug 01, 2017: llumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 123

Aug 01, 2017: Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 124

Apr 25, 2017: Illumina Reports Financial Results for First Quarter of Fiscal Year 2017 125

Jan 31, 2017: Illumina Reports Full Financial Results for Fourth Quarter and Fiscal Year 2016 126

Research And Development 128

Feb 28, 2017: Illumina Announces the iHope Network, an Expansion of Its iHope Philanthropic Clinical Whole Genome Sequencing Program 128

Corporate Communications 129

Mar 12, 2018: Illumina Names Dr. Phil Febbo Chief Medical Officer 129

Dec 11, 2017: Illumina Names Aimee Hoyt Chief People Officer, Bringing 20+ Years of Senior Human Resources Leadership from Global Technology Companies 130

Nov 08, 2017: Illumina Names Gary S. Guthart, Ph.D., to its Board of Directors, Adding Decades of Leadership Experience in Healthcare 131

May 22, 2017: Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise and Strong Commercial Leadership Experience to the Role 132

Feb 20, 2017: Illumina Names John W. Thompson to Its Board of Directors, Bringing More Than 40 Years of Technology Leadership to Illumina 133

Jan 27, 2017: Illumina Names Caroline Dorsa to Its Board of Directors, Adding Over 30 Years of Leadership Experience in the Healthcare, Telecommunications and Energy Industries 134

Jan 03, 2017: Illumina Taps Garret Hampton, One of the Worlds Leading Clinical Genomics Experts, to Head its Clinical Genomics Unit 135

Legal and Regulatory 136

Jul 03, 2017: Premaitha Health Litigation Update 136

Government and Public Interest 137

Feb 12, 2018: New GUINNESS WORLD RECORDS Title Set for Fastest Genetic Diagnosis 137

Product News 139

Sep 13, 2018: ABclonal Technology unveils Next-Generation Sequencing kits for Illumina sequencing platforms 139

Oct 17, 2017: Dr. David Walt of Wyss Institute to Speak at Powering Precision Health 2017 140

Jul 13, 2017: World-leading Cancer Researchers First in UK to Receive Novaseq-The Latest Genome Sequencing Technology 141

Jan 09, 2017: Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases 143

Jan 09, 2017: Illumina Introduces the NovaSeq Seriesa New Architecture Designed to Usher in the $100 Genome 144

Other Significant Developments 145

Oct 11, 2018: Almac Group Invests in Cutting Edge Next Generation Sequencing Capabilities for Bio Pharma Clients 145

Jul 12, 2018: OrigiMed Collaborates with Illumina to Further Develop and Promote its Advanced Clinical Molecular Tumor Applications 146

May 07, 2018: Genome Medical Enters Employer Market with Diverse Genetic Health Programs and Wave of New Partners 147

Jan 08, 2018: Thermo Fisher Scientific and Illumina Sign Agreement to Provide Research Market Broader Access to Ion AmpliSeq Technology 148

Oct 16, 2017: Illumina Releases NovaSeq S4 Flow Cell and NovaSeq Xp Workflow 149

Jun 26, 2017: Genomics England Adopts Illuminas BaseSpace Variant Interpreter for Cancer 150

Jun 01, 2017: Philips and Illumina team up with Navican, an Intermountain Healthcare Company, to Accelerate the Delivery of Precision Medicine to Health Systems Worldwide 151

Apr 20, 2017: Personalis Orders Ten Illumina NovaSeq 6000 Systems for Immuno-Oncology Genomics and Large-Scale Whole Genome Sequencing 153

Apr 10, 2017: CloudHealth Genomics Makes China's First Sequencing Data Available Using Illumina's NovaSeq 6000 154

Apr 03, 2017: Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC 155

Apr 03, 2017: Novogene Adds 25 Illumina NovaSeq Sequencers 156

Appendix 157

Methodology 157

About GlobalData 157

Contact Us 157

Disclaimer 157


List Of Figure

List of Figures

Illumina Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Illumina Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Illumina Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Illumina Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Illumina Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Illumina Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 11

Illumina Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Illumina Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 13


List Of Table

List of Tables

Illumina Inc, Medical Equipment, Key Facts, 2017 2

Illumina Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Illumina Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Illumina Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 11

Illumina Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Illumina Inc, Deals By Market, 2012 to YTD 2018 13

Illumina Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 14

Grail Raises USD300 Million in Series C Financing 19

Cernostics Raises USD2.5 Million in Series A1 Financing 20

SerImmune Raises USD8 Million in Venture Financing 21

Grail Raises USD914 Million in First Tranche of Series B Financing 22

Human Longevity Raises USD220 Million in Series B Financing Round 24

Grail Bio Raises USD100 Million in Series A Financing 26

Vitagene Raises Funds in Financing Round 27

23andMe Raises USD115 Million in Series E Financing 28

Baebies Raises USD13 Million in Financing Round 30

Verinata Health (Artemis Health) Secures USD1.2 Million in Seed Funding 31

Oxford Nanopore Raises USD 64 Million In Venture Financing 32

GenoLogics Life Sciences Raises USD0.9 Million in Venture Financing 34

GenoLogics Life Sciences Raises Additional USD0.5 Million in Venture Financing 35

GenoLogics Life Sciences Raises USD1.3 Million in Venture Financing 36

Mubadala GE Capital and SoftBank Vision Fund May Acquire GRAIL 37

Vitrolife Enters into Licensing Agreement with Illumina 38

CareDx Enters into Licensing and Commercialization Agreement with Illumina 39

Skyline Medical Enters into Licensing Agreement with Illumina 40

Illumina Enters Into Licensing Agreement With Quest Diagnostics 41

Peter MacCallum Cancer Centre Enters Into Licensing Agreement With GenoLogics Life Sciences Software For Clarity LIMS 42

Genecast Biotechnology Enters into Partnership Agreement with Illumina 43

Yissum Enters into Agreement with GRAIL 44

Bristol-Myers Squibb and Illumina Enter into Partnership Agreement 45

Illumina and Loxo Oncology Enter into Partnership 46

Illumina and KingMed Diagnostics Enter into Agreement 47

Illumina Enters into Agreement with Pillar Biosciences 48

Edico Genome Enters Into Partnership With Fabric Genomics 49

Hamilton Robotics Partners with Illumina 50

Lucigen Enters into Distribution Agreement with Illumina 51

Kailos Genetics Enters into Co-Marketing Agreement with Illumina 52

Analytik Jena Enters into Co-Development Agreement with Illumina 53

Bristol-Myers Squibb Plans to Enter into Research Agreement with GRAIL 54

Invivoscribe Tech Enters into Agreement with Illumina 55

IBM Watson Health Enters into Agreement with Illumina 56

Koninklijke Philips Enters into Agreement with Illumina 57

Illumina Enters into Agreement with Mayo Clinic 58

Q2 Solutions Enters into Co-Development Agreement with Illumina 59

Sophia Genetics Enters into Co-Marketing Agreement with Illumina 60

Illumina Enters into Agreement with FlowJo 61

Personal Genome Diagnostics Enters into Co-Development Agreement with Illumina 62

MolecularMD Enters into Agreement with Illumina 63

ArcherDX Enters into Co-Development Agreement with Illumina 64

Genomics England Partners with Illumina 65

Bio-Rad Laboratories Enters into Partnership with Illumina 66

Novogene Enters into Co-Development Agreement with Illumina 67

Almac Diagnostics Enters into Agreement with Illumina 68

Centers for Disease Control and Prevention Enters into Research Agreement with Edico Genome 69

Asuragen to Enter into Agreement with Illumina 70

Edico Genome Enters into Agreement with HudsonAlpha Institute for Biotechnology 71

Illumina Enters into Co-Development Agreement with Annoroad Gene Technology 72

Merck Serono Enters into Co- Development Agreement with Illumina 73

Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT 74

BioMerieux Enters into Co-Development Agreement with Illumina 75

Sequenta Enters into Agreement with Illumina to Commercialize In Vitro Diagnostic Kit 76

Reprogenetics Enters into R&D Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems 77

HTG Molecular Diagnostics Amends its Agreement with Illumina to Develop IVD Kits for Sequencing Tests 78

Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 79

Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 80

Pathogenica Enters Into Co-Marketing Agreement With Illumina 81

Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 82

Illumina Enters Into Co-Marketing Agreement With Hamilton Robotics 83

SynapDx Enters Into Co-Development Agreement With Illumina For Autism Diagnostic Tools 84

Sonic Healthcare Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 85

Newbridge Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 86

NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers 87

PerkinElmer Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 88

NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 89

Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 90

GenMark Diagnostics Enters Into Co-Development Agreement With Advanced Liquid Logic For Integrated Diagnostic Platform 91

Grail Merges with Cirina 92

Grail May Raise USD1 Billion in IPO 93

Illumina Prices Private Placement of Notes Due 2023 for USD650 Million 94

Illumina Raises USD550 Million in Private Placement of Notes Due 2019 96

Illumina Raises USD450 Million in Private Placement of 0.5% Notes Due 2021 97

Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 98

Pathway Genomics Acquires MiSeqDx From Illumina 99

Novogene Acquires HiSeq X Ten Sequencing System From Illumina 100

Illumina Acquires Edico Genome 101

Thermo Fisher Scientific May Acquire Illumina for USD30 Billion 102

Illumina Acquires Conexio Genomics 103

Illumina Acquires Myraqa, In-Vitro Diagnostics Company 104

Illumina Acquires NextBio, Clinical and Genomic Informatics Company 105

Illumina Completes Sale Of 13.5% Stake In Oxford Nanopore For USD 91 Million 106

Illumina Acquires Advanced Liquid Logic 107

Illumina Completes Acquisition Of Verinata Health 108

Illumina Acquires Moleculo, Long-Read Sequencing Technology Developer 110

Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization Screening Solutions 111

Illumina Inc, Key Competitors 112

Illumina Inc, Key Employees 113

Illumina Inc, Other Locations 114

Illumina Inc, Subsidiaries 114

Illumina Inc, Joint Venture 116

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Illumina Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company's portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina caters its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations. The company sells its products through direct sales and distributors in the Americas, Asia-Pacific, Europe, the Middle East and Africa. Illumina is headquartered in San Diego, California, the US.

Illumina Inc (ILMN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 8

Illumina Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Illumina Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 11

Illumina Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Illumina Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 13

Illumina Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 14

Illumina Inc, Medical Equipment, Deal Details 19

Venture Financing 19

Grail Raises USD300 Million in Series C Financing 19

Cernostics Raises USD2.5 Million in Series A1 Financing 20

SerImmune Raises USD8 Million in Venture Financing 21

Grail Raises USD914 Million in First Tranche of Series B Financing 22

Human Longevity Raises USD220 Million in Series B Financing Round 24

Grail Bio Raises USD100 Million in Series A Financing 26

Vitagene Raises Funds in Financing Round 27

23andMe Raises USD115 Million in Series E Financing 28

Baebies Raises USD13 Million in Financing Round 30

Verinata Health (Artemis Health) Secures USD1.2 Million in Seed Funding 31

Oxford Nanopore Raises USD 64 Million In Venture Financing 32

GenoLogics Life Sciences Raises USD0.9 Million in Venture Financing 34

GenoLogics Life Sciences Raises Additional USD0.5 Million in Venture Financing 35

GenoLogics Life Sciences Raises USD1.3 Million in Venture Financing 36

Private Equity 37

Mubadala GE Capital and SoftBank Vision Fund May Acquire GRAIL 37

Partnerships 38

Vitrolife Enters into Licensing Agreement with Illumina 38

CareDx Enters into Licensing and Commercialization Agreement with Illumina 39

Skyline Medical Enters into Licensing Agreement with Illumina 40

Illumina Enters Into Licensing Agreement With Quest Diagnostics 41

Peter MacCallum Cancer Centre Enters Into Licensing Agreement With GenoLogics Life Sciences Software For Clarity LIMS 42

Genecast Biotechnology Enters into Partnership Agreement with Illumina 43

Yissum Enters into Agreement with GRAIL 44

Bristol-Myers Squibb and Illumina Enter into Partnership Agreement 45

Illumina and Loxo Oncology Enter into Partnership 46

Illumina and KingMed Diagnostics Enter into Agreement 47

Illumina Enters into Agreement with Pillar Biosciences 48

Edico Genome Enters Into Partnership With Fabric Genomics 49

Hamilton Robotics Partners with Illumina 50

Lucigen Enters into Distribution Agreement with Illumina 51

Kailos Genetics Enters into Co-Marketing Agreement with Illumina 52

Analytik Jena Enters into Co-Development Agreement with Illumina 53

Bristol-Myers Squibb Plans to Enter into Research Agreement with GRAIL 54

Invivoscribe Tech Enters into Agreement with Illumina 55

IBM Watson Health Enters into Agreement with Illumina 56

Koninklijke Philips Enters into Agreement with Illumina 57

Illumina Enters into Agreement with Mayo Clinic 58

Q2 Solutions Enters into Co-Development Agreement with Illumina 59

Sophia Genetics Enters into Co-Marketing Agreement with Illumina 60

Illumina Enters into Agreement with FlowJo 61

Personal Genome Diagnostics Enters into Co-Development Agreement with Illumina 62

MolecularMD Enters into Agreement with Illumina 63

ArcherDX Enters into Co-Development Agreement with Illumina 64

Genomics England Partners with Illumina 65

Bio-Rad Laboratories Enters into Partnership with Illumina 66

Novogene Enters into Co-Development Agreement with Illumina 67

Almac Diagnostics Enters into Agreement with Illumina 68

Centers for Disease Control and Prevention Enters into Research Agreement with Edico Genome 69

Asuragen to Enter into Agreement with Illumina 70

Edico Genome Enters into Agreement with HudsonAlpha Institute for Biotechnology 71

Illumina Enters into Co-Development Agreement with Annoroad Gene Technology 72

Merck Serono Enters into Co- Development Agreement with Illumina 73

Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT 74

BioMerieux Enters into Co-Development Agreement with Illumina 75

Sequenta Enters into Agreement with Illumina to Commercialize In Vitro Diagnostic Kit 76

Reprogenetics Enters into R&D Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems 77

HTG Molecular Diagnostics Amends its Agreement with Illumina to Develop IVD Kits for Sequencing Tests 78

Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 79

Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 80

Pathogenica Enters Into Co-Marketing Agreement With Illumina 81

Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 82

Illumina Enters Into Co-Marketing Agreement With Hamilton Robotics 83

SynapDx Enters Into Co-Development Agreement With Illumina For Autism Diagnostic Tools 84

Sonic Healthcare Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 85

Newbridge Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 86

NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers 87

PerkinElmer Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 88

NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 89

Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 90

GenMark Diagnostics Enters Into Co-Development Agreement With Advanced Liquid Logic For Integrated Diagnostic Platform 91

Merger 92

Grail Merges with Cirina 92

Equity Offering 93

Grail May Raise USD1 Billion in IPO 93

Debt Offering 94

Illumina Prices Private Placement of Notes Due 2023 for USD650 Million 94

Illumina Raises USD550 Million in Private Placement of Notes Due 2019 96

Illumina Raises USD450 Million in Private Placement of 0.5% Notes Due 2021 97

Asset Transactions 98

Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 98

Pathway Genomics Acquires MiSeqDx From Illumina 99

Novogene Acquires HiSeq X Ten Sequencing System From Illumina 100

Acquisition 101

Illumina Acquires Edico Genome 101

Thermo Fisher Scientific May Acquire Illumina for USD30 Billion 102

Illumina Acquires Conexio Genomics 103

Illumina Acquires Myraqa, In-Vitro Diagnostics Company 104

Illumina Acquires NextBio, Clinical and Genomic Informatics Company 105

Illumina Completes Sale Of 13.5% Stake In Oxford Nanopore For USD 91 Million 106

Illumina Acquires Advanced Liquid Logic 107

Illumina Completes Acquisition Of Verinata Health 108

Illumina Acquires Moleculo, Long-Read Sequencing Technology Developer 110

Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization Screening Solutions 111

Illumina Inc-Key Competitors 112

Illumina Inc-Key Employees 113

Illumina Inc-Locations And Subsidiaries 114

Head Office 114

Other Locations & Subsidiaries 114

Joint Venture 116

Recent Developments 117

Financial Announcements 117

Jul 30, 2018: Illumina Reports Financial Results for Second Quarter of Fiscal Year 2018 117

Apr 24, 2018: Illumina Reports Financial Results for First Quarter of Fiscal Year 2018 119

Jan 30, 2018: Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2017 120

Oct 24, 2017: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2017 122

Aug 01, 2017: llumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 123

Aug 01, 2017: Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 124

Apr 25, 2017: Illumina Reports Financial Results for First Quarter of Fiscal Year 2017 125

Jan 31, 2017: Illumina Reports Full Financial Results for Fourth Quarter and Fiscal Year 2016 126

Research And Development 128

Feb 28, 2017: Illumina Announces the iHope Network, an Expansion of Its iHope Philanthropic Clinical Whole Genome Sequencing Program 128

Corporate Communications 129

Mar 12, 2018: Illumina Names Dr. Phil Febbo Chief Medical Officer 129

Dec 11, 2017: Illumina Names Aimee Hoyt Chief People Officer, Bringing 20+ Years of Senior Human Resources Leadership from Global Technology Companies 130

Nov 08, 2017: Illumina Names Gary S. Guthart, Ph.D., to its Board of Directors, Adding Decades of Leadership Experience in Healthcare 131

May 22, 2017: Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise and Strong Commercial Leadership Experience to the Role 132

Feb 20, 2017: Illumina Names John W. Thompson to Its Board of Directors, Bringing More Than 40 Years of Technology Leadership to Illumina 133

Jan 27, 2017: Illumina Names Caroline Dorsa to Its Board of Directors, Adding Over 30 Years of Leadership Experience in the Healthcare, Telecommunications and Energy Industries 134

Jan 03, 2017: Illumina Taps Garret Hampton, One of the Worlds Leading Clinical Genomics Experts, to Head its Clinical Genomics Unit 135

Legal and Regulatory 136

Jul 03, 2017: Premaitha Health Litigation Update 136

Government and Public Interest 137

Feb 12, 2018: New GUINNESS WORLD RECORDS Title Set for Fastest Genetic Diagnosis 137

Product News 139

Sep 13, 2018: ABclonal Technology unveils Next-Generation Sequencing kits for Illumina sequencing platforms 139

Oct 17, 2017: Dr. David Walt of Wyss Institute to Speak at Powering Precision Health 2017 140

Jul 13, 2017: World-leading Cancer Researchers First in UK to Receive Novaseq-The Latest Genome Sequencing Technology 141

Jan 09, 2017: Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases 143

Jan 09, 2017: Illumina Introduces the NovaSeq Seriesa New Architecture Designed to Usher in the $100 Genome 144

Other Significant Developments 145

Oct 11, 2018: Almac Group Invests in Cutting Edge Next Generation Sequencing Capabilities for Bio Pharma Clients 145

Jul 12, 2018: OrigiMed Collaborates with Illumina to Further Develop and Promote its Advanced Clinical Molecular Tumor Applications 146

May 07, 2018: Genome Medical Enters Employer Market with Diverse Genetic Health Programs and Wave of New Partners 147

Jan 08, 2018: Thermo Fisher Scientific and Illumina Sign Agreement to Provide Research Market Broader Access to Ion AmpliSeq Technology 148

Oct 16, 2017: Illumina Releases NovaSeq S4 Flow Cell and NovaSeq Xp Workflow 149

Jun 26, 2017: Genomics England Adopts Illuminas BaseSpace Variant Interpreter for Cancer 150

Jun 01, 2017: Philips and Illumina team up with Navican, an Intermountain Healthcare Company, to Accelerate the Delivery of Precision Medicine to Health Systems Worldwide 151

Apr 20, 2017: Personalis Orders Ten Illumina NovaSeq 6000 Systems for Immuno-Oncology Genomics and Large-Scale Whole Genome Sequencing 153

Apr 10, 2017: CloudHealth Genomics Makes China's First Sequencing Data Available Using Illumina's NovaSeq 6000 154

Apr 03, 2017: Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC 155

Apr 03, 2017: Novogene Adds 25 Illumina NovaSeq Sequencers 156

Appendix 157

Methodology 157

About GlobalData 157

Contact Us 157

Disclaimer 157


List Of Figure

List of Figures

Illumina Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Illumina Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Illumina Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Illumina Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Illumina Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Illumina Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 11

Illumina Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Illumina Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 13


List Of Table

List of Tables

Illumina Inc, Medical Equipment, Key Facts, 2017 2

Illumina Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Illumina Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Illumina Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 11

Illumina Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Illumina Inc, Deals By Market, 2012 to YTD 2018 13

Illumina Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 14

Grail Raises USD300 Million in Series C Financing 19

Cernostics Raises USD2.5 Million in Series A1 Financing 20

SerImmune Raises USD8 Million in Venture Financing 21

Grail Raises USD914 Million in First Tranche of Series B Financing 22

Human Longevity Raises USD220 Million in Series B Financing Round 24

Grail Bio Raises USD100 Million in Series A Financing 26

Vitagene Raises Funds in Financing Round 27

23andMe Raises USD115 Million in Series E Financing 28

Baebies Raises USD13 Million in Financing Round 30

Verinata Health (Artemis Health) Secures USD1.2 Million in Seed Funding 31

Oxford Nanopore Raises USD 64 Million In Venture Financing 32

GenoLogics Life Sciences Raises USD0.9 Million in Venture Financing 34

GenoLogics Life Sciences Raises Additional USD0.5 Million in Venture Financing 35

GenoLogics Life Sciences Raises USD1.3 Million in Venture Financing 36

Mubadala GE Capital and SoftBank Vision Fund May Acquire GRAIL 37

Vitrolife Enters into Licensing Agreement with Illumina 38

CareDx Enters into Licensing and Commercialization Agreement with Illumina 39

Skyline Medical Enters into Licensing Agreement with Illumina 40

Illumina Enters Into Licensing Agreement With Quest Diagnostics 41

Peter MacCallum Cancer Centre Enters Into Licensing Agreement With GenoLogics Life Sciences Software For Clarity LIMS 42

Genecast Biotechnology Enters into Partnership Agreement with Illumina 43

Yissum Enters into Agreement with GRAIL 44

Bristol-Myers Squibb and Illumina Enter into Partnership Agreement 45

Illumina and Loxo Oncology Enter into Partnership 46

Illumina and KingMed Diagnostics Enter into Agreement 47

Illumina Enters into Agreement with Pillar Biosciences 48

Edico Genome Enters Into Partnership With Fabric Genomics 49

Hamilton Robotics Partners with Illumina 50

Lucigen Enters into Distribution Agreement with Illumina 51

Kailos Genetics Enters into Co-Marketing Agreement with Illumina 52

Analytik Jena Enters into Co-Development Agreement with Illumina 53

Bristol-Myers Squibb Plans to Enter into Research Agreement with GRAIL 54

Invivoscribe Tech Enters into Agreement with Illumina 55

IBM Watson Health Enters into Agreement with Illumina 56

Koninklijke Philips Enters into Agreement with Illumina 57

Illumina Enters into Agreement with Mayo Clinic 58

Q2 Solutions Enters into Co-Development Agreement with Illumina 59

Sophia Genetics Enters into Co-Marketing Agreement with Illumina 60

Illumina Enters into Agreement with FlowJo 61

Personal Genome Diagnostics Enters into Co-Development Agreement with Illumina 62

MolecularMD Enters into Agreement with Illumina 63

ArcherDX Enters into Co-Development Agreement with Illumina 64

Genomics England Partners with Illumina 65

Bio-Rad Laboratories Enters into Partnership with Illumina 66

Novogene Enters into Co-Development Agreement with Illumina 67

Almac Diagnostics Enters into Agreement with Illumina 68

Centers for Disease Control and Prevention Enters into Research Agreement with Edico Genome 69

Asuragen to Enter into Agreement with Illumina 70

Edico Genome Enters into Agreement with HudsonAlpha Institute for Biotechnology 71

Illumina Enters into Co-Development Agreement with Annoroad Gene Technology 72

Merck Serono Enters into Co- Development Agreement with Illumina 73

Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT 74

BioMerieux Enters into Co-Development Agreement with Illumina 75

Sequenta Enters into Agreement with Illumina to Commercialize In Vitro Diagnostic Kit 76

Reprogenetics Enters into R&D Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems 77

HTG Molecular Diagnostics Amends its Agreement with Illumina to Develop IVD Kits for Sequencing Tests 78

Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 79

Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 80

Pathogenica Enters Into Co-Marketing Agreement With Illumina 81

Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 82

Illumina Enters Into Co-Marketing Agreement With Hamilton Robotics 83

SynapDx Enters Into Co-Development Agreement With Illumina For Autism Diagnostic Tools 84

Sonic Healthcare Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 85

Newbridge Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 86

NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers 87

PerkinElmer Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 88

NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 89

Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 90

GenMark Diagnostics Enters Into Co-Development Agreement With Advanced Liquid Logic For Integrated Diagnostic Platform 91

Grail Merges with Cirina 92

Grail May Raise USD1 Billion in IPO 93

Illumina Prices Private Placement of Notes Due 2023 for USD650 Million 94

Illumina Raises USD550 Million in Private Placement of Notes Due 2019 96

Illumina Raises USD450 Million in Private Placement of 0.5% Notes Due 2021 97

Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 98

Pathway Genomics Acquires MiSeqDx From Illumina 99

Novogene Acquires HiSeq X Ten Sequencing System From Illumina 100

Illumina Acquires Edico Genome 101

Thermo Fisher Scientific May Acquire Illumina for USD30 Billion 102

Illumina Acquires Conexio Genomics 103

Illumina Acquires Myraqa, In-Vitro Diagnostics Company 104

Illumina Acquires NextBio, Clinical and Genomic Informatics Company 105

Illumina Completes Sale Of 13.5% Stake In Oxford Nanopore For USD 91 Million 106

Illumina Acquires Advanced Liquid Logic 107

Illumina Completes Acquisition Of Verinata Health 108

Illumina Acquires Moleculo, Long-Read Sequencing Technology Developer 110

Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization Screening Solutions 111

Illumina Inc, Key Competitors 112

Illumina Inc, Key Employees 113

Illumina Inc, Other Locations 114

Illumina Inc, Subsidiaries 114

Illumina Inc, Joint Venture 116

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Illumina Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.